Oxford Covid-19 trial will look at interim Phase III data after 53 infections - investigator
Coronavirus chronicle
19 November, 2020, 05:15 pm
Last modified: 19 November, 2020, 05:20 pm
The Oxford Vaccine Group’s director Andrew Pollard said there were “lots of cases” of infections in its Phase III trial in Britain, Brazil and South Africa
Representational Image. Photo: Collected
Oxford University will start an initial analysis of data from its late-stage trial of the experimental Covid-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study's chief investigator said on Thursday.
The Oxford Vaccine Group's director Andrew Pollard said there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa.
The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.